1. Metabolic Enzyme/Protease MAPK/ERK Pathway PI3K/Akt/mTOR Stem Cell/Wnt Apoptosis Protein Tyrosine Kinase/RTK
  2. Endogenous Metabolite MAP3K Akt Mitochondrial Metabolism ERK Apoptosis ROS Kinase
  3. Phosphocreatine

Phosphocreatine  (Synonyms: 磷酸胍酸; Creatine phosphate; Creatinephosphoric acid)

目录号: HY-D0885 纯度: ≥95.0%
COA 产品使用指南 技术支持

Phosphocreatine (creatine phosphate) 是一种存在于脊椎动物骨骼肌中的有机化合物。Phosphocreatine 增强抗氧化活性,激活 TAK1 通路以保护心脏。Phosphocreatine 通过 Akt 介导的 Nrf2/HO-1 途径使线粒体功能正常化并减少氧化应激。Phosphocreatine 通过 ERK 介导的 Nrf-2/HO-1 途径抑制细胞凋亡 (Apoptosis) 和 ROS (Reactive Oxygen Species) 的产生,从而保护肾脏。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Phosphocreatine Chemical Structure

Phosphocreatine Chemical Structure

CAS No. : 67-07-2

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
100 mg ¥500
In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

MCE 顾客使用本产品发表的 1 篇科研文献

查看 MAP3K 亚型特异性产品:

查看 Akt 亚型特异性产品:

查看 ERK 亚型特异性产品:

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Phosphocreatine (creatine phosphate) is an organic compound found in vertebrate skeletal muscles. Phosphocreatine enhances antioxidant activity, and activates the TAK1 pathway to protect the heart. Phosphocreatine normalizing mitochondrial function and reducing oxidative stress via Akt mediated Nrf2/HO-1 pathway. Phosphocreatine provides renal protection by suppressing Apoptosis and ROS (Reactive Oxygen Species) generation through ERK mediated mediated Nrf-2/HO-1 pathway.[1][2][3][4].

IC50 & Target

Human Endogenous Metabolite

 

体外研究
(In Vitro)

Phosphocreatine (0-1 mM, 24 h) 通过靶向 TAK1 揭示了抗氧化、抗凋亡和抗坏死性凋亡的作用,以保护 H9c2 细胞免受 DOX (Doxorubicin) (HY-15142A) 诱导的心肌细胞损伤[2]
Phosphocreatine (0-1 mM, 24 h) 通过增加抗氧化活性来缓解氧化应激,随后将 TAK1 的表达水平恢复到基线水平,并减少 DOX 诱导的心肌损伤中的细胞凋亡和程序性死亡[2]
Phosphocreatine (5-20 mM, 24 h) 可减轻 MGO (Methylglyoxal) (HY-106634) 诱导的 PC12 细胞损伤和抑制 PC-12 细胞凋亡[3]
Phosphocreatine (5-20 mM, 24 h) 可防止MGO (Methylglyoxal) 诱导损伤的PC-12 细胞线粒体膜通透性丧失[3]
Phosphocreatine (5-20 mM, 2 h) 对 PC-12 细胞的神经保护作用依赖于通过 Akt 介导的 Nrf2/HO- 1途径使线粒体功能正常化和减少氧化应激[3]
Phosphocreatine (5-40 mM, 24 h) 在不同浓度下可能有助于保护 NRK-52E 细胞免受 MGO 诱导的肾损伤[4]
Phosphocreatine (10-40 mM, 4 h) 抑制肾脏氧化应激代谢物[4]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[3][4]

Cell Line: PC-12, NRK-52E cells
Concentration: 0, 5, 10, 20, 40 mM
Incubation Time: 24 h
Result: Was not toxic to PC-12 cells under the treatment conditions.
Significantly increased PC-12 cell viability at the concentrations of 5, 10 and 20 mM compared with MGO (Methylglyoxal) (HY-106634) groups.
Contributed to protection of the NRK-52E cells against MGO-induced kidney injury.

Apoptosis Analysis[3][4]

Cell Line: PC-12, NRK-52E cells
Concentration: 5, 10, 20, 40 mM
Incubation Time: 2 h
Result: Significantly suppressed the enhanced early apoptosis in PC-12 cells in a dose-dependent manner.
Increased the expression of Bcl-2, procaspase-3 and procaspase-9 in NRK-52E cells.
Decreased the expression of Bax and cleaved caspase-3 in NRK-52E cells..
Suppressed karyorrhexis and karyopyknosis in NRK-52E cells..
Decreased the apoptotic rate compared with MGO-treated cells in NRK-52E cells..
Prevented the losing of MMP (mitochondrial membrane potential) in NRK-52E cells.

Western Blot Analysis[3][4]

Cell Line: PC-12, NRK-52E cells
Concentration: 20, 40 mM
Incubation Time: 24 h
Result: Increased the expression levels of Akt, Nrf2 (nuclear factor (erythroid-derived-2)-like 2 (Nrf2)) and HO-1 (Hemeoxygenase-1) in PC12 cells.
Increased the expression of nuclear Nrf2 levels, and decreased Nrf2 level in PC12 cells cytoplasm.
Increased the expression of p-Akt, HO-1 and Nrf2 with compared with pre-treatment for 2 h with LY294002 (a PI3K inhibitor) in PC12 cells.
Significantly increased Bcl-2 and procaspase-9 levels and decreased Bax, cleaved caspase-9 and cleaved caspase-3 C level in NRK-52E cells.
Decreased the expression of p-ERK and increased the Nrf2 and HO-1 expressions in NRK-52E cells.
体内研究
(In Vivo)

Phosphocreatine (200 mg/kg, i.p., 每隔一天一次, 7 周) 不仅减轻了氧化应激和心肌细胞凋亡,而且挽救了 DOX 诱导的大鼠心脏毒性中的心肌坏死[2]
Phosphocreatine (20-40 mg/kg, i.v., 每天, 6 周) 对 SD (Sprague-Dawley) 大鼠的肾组织具有保护作用,可预防糖尿病肾病[4]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Sprague Dawley (SD) rats, i.p., normal saline, 3 times; i.p., DOX 2 mg/kg, 7 times; i.p., normal saline, 3 times [2].
Dosage: 200 mg/kg
Administration: i.p., once every other day, 7 weeks
Result: Improved the heart function abnormality.
Lowered myocardial apoptosis.
Recovered the expression of Nrf2, SOD, FoxO3a and diminished C-Casp3, Bax/Bcl2 in the myocardial tissue of rats.
Markedly improved myocardial necroptosis, as indicated by decreasing expression of RIP3 and CaMKII.
Increased expression level of TAK1.
Animal Model: Male Sprague Dawley (SD) rats, i.p., 70 mg/kg (STZ(Streptozotocin) (HY-13753)), daily, 6 weeks [4].
Dosage: 20, 40 mg/kg
Administration: i.p., daily, 6 weeks
Result: Reduced hyperglycemia compared with STZ (Streptozotocin) (HY-13753) -treated rats.
Increased the weight of rats gradually compared with STZ (Streptozotocin) (HY-13753) group.
Decreased kidney weight index (kidney weight/body weight).
Decreased MDA level and increased of GSH and SOD levels compared with STZ group.
Decreased the apoptotic rate compared with MGO-treated groups.
Clinical Trial
分子量

211.11

Formula

C4H10N3O5P

CAS 号
性状

固体

颜色

White to off-white

中文名称

磷酸胍酸

结构分类
初始来源

skeletal muscles of vertebrates

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
细胞实验: 

H2O 中的溶解度 : 175 mg/mL (828.95 mM; 超声助溶)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 4.7369 mL 23.6843 mL 47.3687 mL
5 mM 0.9474 mL 4.7369 mL 9.4737 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

* 备注:如您选择水作为储备液,请稀释至工作液后,再用 0.22 μm 的滤膜过滤除菌后使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物溶解方案计算器
请输入动物实验的基本信息:

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

由于实验过程有损耗,建议您多配一只动物的量
计算结果
工作液所需浓度 : mg/mL
该产品水溶性佳,请具体参考实测 水 / PBS / Saline 中的溶解度数据。
您所需的储备液浓度超过该产品的实测溶解度,如有需要,请与 MCE 中国技术支持联系。
纯度 & 产品资料

纯度: ≥95.0%

参考文献

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
H2O 1 mM 4.7369 mL 23.6843 mL 47.3687 mL 118.4217 mL
5 mM 0.9474 mL 4.7369 mL 9.4737 mL 23.6843 mL
10 mM 0.4737 mL 2.3684 mL 4.7369 mL 11.8422 mL
15 mM 0.3158 mL 1.5790 mL 3.1579 mL 7.8948 mL
20 mM 0.2368 mL 1.1842 mL 2.3684 mL 5.9211 mL
25 mM 0.1895 mL 0.9474 mL 1.8947 mL 4.7369 mL
30 mM 0.1579 mL 0.7895 mL 1.5790 mL 3.9474 mL
40 mM 0.1184 mL 0.5921 mL 1.1842 mL 2.9605 mL
50 mM 0.0947 mL 0.4737 mL 0.9474 mL 2.3684 mL
60 mM 0.0789 mL 0.3947 mL 0.7895 mL 1.9737 mL
80 mM 0.0592 mL 0.2961 mL 0.5921 mL 1.4803 mL
100 mM 0.0474 mL 0.2368 mL 0.4737 mL 1.1842 mL

* 备注:如您选择水作为储备液,请稀释至工作液后,再用 0.22 μm 的滤膜过滤除菌后使用。

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Phosphocreatine
目录号:
HY-D0885
需求量: